Tb-500 Dosage
TB-500 Dosage: What the Research Actually Reports
The short answer
TB-500 dosage has no established human figure. TB-500 is a lab-made peptide sold as a thymosin beta-4 fragment or analog, and thymosin beta-4 is an actin-sequestering peptide the review literature links to cell migration and tissue-repair models (Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294). There are no completed, published human dosing trials for the TB-500 fragment, so any figure presented as a "standard dose" is not backed by controlled clinical research. Most of what is known comes from animal work reported on a weight-based (mg/kg) basis that does not convert to a fixed human amount, so any personal-use question belongs with a qualified clinician, not a website.
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is TB-500, and how does it relate to thymosin beta-4?
TB-500 is a synthetic peptide commonly described as being based on the actin-binding region of thymosin beta-4, a naturally occurring peptide the research literature associates with tissue repair (Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294).
Thymosin beta-4 is a small peptide (about 43 amino acids) that the review literature describes as widely present inside many cell types, where it binds and regulates actin, a structural protein cells use to move and reorganize (Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294; Xing et al., Front Endocrinol 2021). In cell and animal models, this activity is studied in the setting of cell migration, blood-vessel formation, and wound repair. One controlled rodent study, for example, reported that topical or intraperitoneal thymosin beta-4 increased reepithelialization by about 42% at day 4 and up to about 61% at day 7 versus saline controls (Malinda et al., J Invest Dermatol 1999; PMID 10469335). Those figures refer to the parent peptide, thymosin beta-4, in animals, not a human result for the TB-500 fragment.
One point causes real confusion for anyone reading a dosage figure: products labeled "TB-500" are not always the same molecule. Some contain a fragment, and some contain the full-length peptide. That matters, because a number written on a label or forum post may not even refer to the same compound studied in a given paper.
Is there a standard TB-500 dosage in humans?
No. There are no completed, published human dosing trials that establish a standard TB-500 dosage, so any "standard" figure you see is not drawn from controlled clinical research.
The wider thymosin beta-4 literature is dominated by laboratory and animal studies rather than large human dosing trials (Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294). For the TB-500 fragment specifically, publicly available controlled dosing data in people is lacking. This is the honest state of the evidence, and it is the reason this page does not print a milligram figure and call it a dose.
The ranges discussed below reflect only what published studies and commonly studied research protocols report, and for TB-500 in humans that record is effectively empty. This is educational, not a prescription or a personal recommendation.
Numbers do circulate in non-clinical sources. Those figures are not the same as research-reported doses from a named trial with a citation, and Peptara Labs does not reproduce them as guidance. Treating anecdote as if it were trial data is exactly the gap this page exists to close.
What does animal research report about thymosin beta-4 dosing?
Animal studies generally report doses on a weight-based basis (amounts scaled to body weight, written as mg/kg) and deliver the peptide by injection or topically depending on the injury model, which does not translate to a single fixed human dose (Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294; Malinda et al., J Invest Dermatol 1999; PMID 10469335).
Weight-based animal dosing does not convert cleanly to people for several reasons: species differ in how they clear a peptide, the human pharmacokinetics of the TB-500 fragment are not established, and scaling between species is not a simple multiplication. Specific numeric ranges do appear in the primary animal literature, but they require verification against the original papers and are not printed here as personal-use guidance, because a weight-based animal figure is not a human dose.
TB-500 dosing evidence at a glance
The table below shows where dosing context comes from and, plainly, where it does not exist. The Source column names the basis for each row.
| Setting | Reported unit basis | Human dosing established? | Source |
|---|---|---|---|
| Thymosin beta-4 biology (mechanism) | Not a dosing context | No | Goldstein et al., Expert Opin Biol Ther 2012; PMID 22074294 |
| Animal tissue-repair models | Weight-based, mg/kg, by injection or topical | Does not convert to a fixed human dose | Malinda et al., J Invest Dermatol 1999; PMID 10469335 |
| TB-500 fragment, humans | No published controlled trials | None established | No completed human trials located |
| BPC-157 (comparison peptide) | Animal-dominant; human data very limited | None established | Sikiric et al., Gut Liver 2020; PMC7096228 |
Why should any personal dose be set by a clinician?
Because TB-500 has no established human dose, no verified human pharmacokinetics, and no standardized concentration or purity across research-grade sources, only a qualified clinician can weigh an individual's situation.
Reconstitution, concentration, and purity vary between sources, long-term human safety data is lacking, and this page is educational rather than a set of instructions. Peptara Labs does not provide dosing advice and does not tell any reader what to take, when, or how. Any research or personal-use question about TB-500 should go to a qualified clinician who can review it in full context.
Keep reading
Related research and verification
Tb-500 Dosage: FAQ
References
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID: 22074294.
- Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. PMID: 10469335.
- Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin beta4. Frontiers in Endocrinology. 2021;12:767785. doi:10.3389/fendo.2021.767785.
- Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167. PMC7096228.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.